These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 26325094)

  • 1. The antipsychotic aripiprazole induces antinociceptive effects: Possible role of peripheral dopamine D2 and serotonin 5-HT1A receptors.
    Almeida-Santos AF; Ferreira RC; Duarte ID; Aguiar DC; Romero TR; Moreira FA
    Eur J Pharmacol; 2015 Oct; 765():300-6. PubMed ID: 26325094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine D2 and serotonin 5-HT1A receptors mediate the actions of aripiprazole in mesocortical and mesoaccumbens transmission.
    Tanahashi S; Yamamura S; Nakagawa M; Motomura E; Okada M
    Neuropharmacology; 2012 Feb; 62(2):765-74. PubMed ID: 21925189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase.
    Bruins Slot LA; De Vries L; Newman-Tancredi A; Cussac D
    Eur J Pharmacol; 2006 Mar; 534(1-3):63-70. PubMed ID: 16497294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peripheral Antinociception Induced by Aripiprazole Is Mediated by the Opioid System.
    Ferreira RCM; Almeida-Santos AF; Duarte IDG; Aguiar DC; Moreira FA; Romero TRL
    Biomed Res Int; 2017; 2017():8109205. PubMed ID: 28758123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of peripheral 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E and 5-HT1F serotonergic receptors in the reduction of nociception in rats.
    Granados-Soto V; Argüelles CF; Rocha-González HI; Godínez-Chaparro B; Flores-Murrieta FJ; Villalón CM
    Neuroscience; 2010 Jan; 165(2):561-8. PubMed ID: 19837141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
    Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A
    Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apomorphine-induced emesis in dogs: differential sensitivity to established and novel dopamine D2/5-HT(1A) antipsychotic compounds.
    Depoortère R; Barret-Grévoz C; Bardin L; Newman-Tancredi A
    Eur J Pharmacol; 2008 Nov; 597(1-3):34-8. PubMed ID: 18773888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. F15063, a potential antipsychotic with dopamine D2/D3 receptor antagonist, 5-HT1A receptor agonist and dopamine D4 receptor partial agonist properties: influence on neuronal firing and neurotransmitter release.
    Assié MB; Mnie-Filali O; Ravailhe V; Benas C; Marien M; Bétry C; Zimmer L; Haddjeri N; Newman-Tancredi A
    Eur J Pharmacol; 2009 Apr; 607(1-3):74-83. PubMed ID: 19326477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator.
    Maeda K; Lerdrup L; Sugino H; Akazawa H; Amada N; McQuade RD; Stensbøl TB; Bundgaard C; Arnt J; Kikuchi T
    J Pharmacol Exp Ther; 2014 Sep; 350(3):605-14. PubMed ID: 24947464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator.
    Maeda K; Sugino H; Akazawa H; Amada N; Shimada J; Futamura T; Yamashita H; Ito N; McQuade RD; Mørk A; Pehrson AL; Hentzer M; Nielsen V; Bundgaard C; Arnt J; Stensbøl TB; Kikuchi T
    J Pharmacol Exp Ther; 2014 Sep; 350(3):589-604. PubMed ID: 24947465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antidepressant-like effect of aripiprazole via 5-HT
    Takahashi K; Nakagawasai O; Nemoto W; Odaira T; Sakuma W; Tan-No K
    J Pharmacol Sci; 2018 Jul; 137(3):241-247. PubMed ID: 30061071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aripiprazole acts as a selective dopamine D2 receptor partial agonist.
    Wood M; Reavill C
    Expert Opin Investig Drugs; 2007 Jun; 16(6):771-5. PubMed ID: 17501690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antipsychotics differ in their ability to internalise human dopamine D2S and human serotonin 5-HT1A receptors in HEK293 cells.
    Heusler P; Newman-Tancredi A; Loock T; Cussac D
    Eur J Pharmacol; 2008 Feb; 581(1-2):37-46. PubMed ID: 18190908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Agonist and antagonist effects of aripiprazole on D₂-like receptors controlling rat brain dopamine synthesis depend on the dopaminergic tone.
    Ma GF; Raivio N; Sabrià J; Ortiz J
    Int J Neuropsychopharmacol; 2014 Oct; 18(4):. PubMed ID: 25522390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repeated administration of aripiprazole produces a sensitization effect in the suppression of avoidance responding and phencyclidine-induced hyperlocomotion and increases D2 receptor-mediated behavioral function.
    Gao J; Qin R; Li M
    J Psychopharmacol; 2015 Apr; 29(4):390-400. PubMed ID: 25586399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bifeprunox and aripiprazole suppress in vivo VTA dopaminergic neuronal activity via D2 and not D3 dopamine autoreceptor activation.
    Etievant A; Bétry C; Arnt J; Haddjeri N
    Neurosci Lett; 2009 Aug; 460(1):82-6. PubMed ID: 19450663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analgesia and pain: Dual effect of dopamine on the peripheral nociceptive system is dependent on D
    Queiroz BFG; Fonseca FCS; Ferreira RCM; Romero TRL; Perez AC; Duarte IDG
    Eur J Pharmacol; 2022 May; 922():174872. PubMed ID: 35300994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel spirohydantoin derivative as a potent multireceptor-active antipsychotic and antidepressant agent.
    Czopek A; Kołaczkowski M; Bucki A; Byrtus H; Pawłowski M; Kazek G; Bojarski AJ; Piaskowska A; Kalinowska-Tłuścik J; Partyka A; Wesołowska A
    Bioorg Med Chem; 2015 Jul; 23(13):3436-47. PubMed ID: 25936259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice.
    Leite JV; Guimarães FS; Moreira FA
    Eur J Pharmacol; 2008 Jan; 578(2-3):222-7. PubMed ID: 18021764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain.
    Li Z; Ichikawa J; Dai J; Meltzer HY
    Eur J Pharmacol; 2004 Jun; 493(1-3):75-83. PubMed ID: 15189766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.